<乌鸦传媒>Program to Reduce Opioid Scripts Post-Surgery Worked for Thyroid Cancer Patients Post-surgical intervention may help to reduce the risk of opioid addiction and overdose Apr 29, 2022
<乌鸦传媒>New Guidelines Target Cancer Risk in Rare GI Syndromes Task force focuses on diagnosis, management of gastrointestinal hamartomatous polyposis syndromes Apr 28, 2022
<乌鸦传媒>When Free Flaps Fail Twice, Another Try Can Be Successful Second salvage attempt worked in 30% of cases Apr 28, 2022
<乌鸦传媒>Topical Antisepsis May Thwart SSIs in Upper Aerodigestive Tract Reconstruction Preoperative topical antisepsis mucosal preparation associated with 51% fewer infections Apr 28, 2022
<乌鸦传媒>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<乌鸦传媒>Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCL Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
<乌鸦传媒>Another Link Between Prostate Cancer Hormone Tx and Impaired Cognition Strongest association with enzalutamide, but survival benefit outweighs effect, specialists say Apr 25, 2022
<乌鸦传媒>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<乌鸦传媒>Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
<乌鸦传媒>What Does It Take to Confirm a Cancer Cluster? Suspicions are raised at a New Jersey high school, but the road ahead is likely a long one Apr 22, 2022
<乌鸦传媒>Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx Consistently low PSA levels failed to signal metastasis Apr 18, 2022
<乌鸦传媒>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<乌鸦传媒>Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy Apr 14, 2022
<乌鸦传媒>BTK Inhibitor Shows Potential in Immune Thrombocytopenia Across doses, 40% of heavily pretreated patients responded to oral rilzabrutinib Apr 13, 2022
<乌鸦传媒>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<乌鸦传媒>Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
<乌鸦传媒>Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
<乌鸦传媒>Genetic Score Shows Promise for Honing PSA Precision Fewer unnecessary biopsies projected with use of genetics-adjusted values Apr 12, 2022
<乌鸦传媒>PARP Inhibitor-Based Triplet Promising in Endometrial Cancer Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients Apr 11, 2022
<乌鸦传媒>Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLC Prolonged tumor response seen in 2-year analysis Apr 11, 2022
<乌鸦传媒>DCIS Recurrence Often Represents a New Primary Breast Cancer Almost a fifth of cases unrelated to primary DCIS, raising questions about current treatment Apr 11, 2022
<乌鸦传媒>Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
<乌鸦传媒>RT Prior to Mastectomy, Reconstruction Shows Promise U.K. study demonstrates low complication rates and good aesthetic results Apr 08, 2022
<乌鸦传媒>Is Sentinel Node Biopsy Necessary for Older Breast Cancer Patients? Study finds positive lymph nodes not an indicator for chemotherapy Apr 07, 2022
<乌鸦传媒>$150K Prostate Cancer Drug Draws New Attention to 'March-In' Rights Advocates want Biden administration to enable Xtandi generics; industry warns against it Apr 06, 2022
<乌鸦传媒>New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
<乌鸦传媒>Black Patients More Often Get 'Substandard' Care for GI Cancers Retrospective study finds worse surgical outcomes, lower odds of receiving chemotherapy Apr 04, 2022
<乌鸦传媒>Living Donor Transplant Promising for CRC With Liver-Only Metastases In small study, researchers see "encouraging" survival outcomes Mar 30, 2022
<乌鸦传媒>Pumping (IV) Iron Linked to Varying Anaphylaxis Risk for Older Adults Study finds risk was low, but unequal across different products Mar 28, 2022
<乌鸦传媒>3D Mammograms Deliver Fewer False-Positive Findings However, half of women will have a false positive with annual screening with DBT Mar 25, 2022
<乌鸦传媒>Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS Mar 25, 2022
<乌鸦传媒>Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
<乌鸦传媒>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
<乌鸦传媒>It's Official: Minimally Invasive Hysterectomy Not Safer in Cervical Cancer Final analysis of LACC trial confirms earlier findings Mar 21, 2022
<乌鸦传媒>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<乌鸦传媒>Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program Mar 20, 2022
<乌鸦传媒>Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial Mar 20, 2022
<乌鸦传媒>Novel ADC Promising in Tough-to-Treat Ovarian Cancer Ocular AEs an issue with mirvetuximab in folate receptor alpha-high platinum-resistant disease Mar 20, 2022
<乌鸦传媒>Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer PRO-based analysis of KEYNOTE-826 trial shows favorable benefit-risk ratio Mar 19, 2022
<乌鸦传媒>Adjuvant Chemo Disappoints in Low-Grade Serous Ovarian Cancer Study suggests no improvement in overall survival Mar 19, 2022
